NCT05814731View on ClinicalTrials.gov

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

NANot yet recruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Haploidentical Stem Cell TransplantationConditioning
Interventions
DRUG

MA-BUCY2

Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2

DRUG

BUCY2

Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2

Trial Locations (1)

710061

First Affiliated Hospital of Xian Jiaotong University, Xi'an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT05814731 - Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT | Biotech Hunter | Biotech Hunter